Boehringer Ingelheim executives hope to be the first to get a biosimilar designated as interchangeable by the end of this year. They say the recent study results were promising for Humira biosimilar Cyltezo. Humira has been the top selling drug for years, with annual sales reported to be around $20 billion, and the price has been rising fast in recent years. FDA has approved several biosimilars of Humira over the past few years, but patent disputes prevent their sale in...